Kuehn Law is investigating Regenxbio, Inc. for allegedly providing false or misleading information about the safety and efficacy of its gene therapy trial for Hurler Syndrome. The lawsuit claims Regenxbio made overly positive statements about the trial's success based on ongoing Phase I/II study data. Shareholders who bought Regenxbio stock before February 9, 2022, are encouraged to contact the law firm to potentially enforce their rights. This case highlights concerns about transparency and accuracy in biotech trial reporting, which can impact investor decisions and market trust.
The Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) is rated Hold because of ongoing market risks despite outperforming peers like SPYI in flat market conditions and showing better drawdown management. The ETF benefits from premium harvesting...
Rentokil Initial PLC reported a 28.9% year-on-year increase in unique website visits in July, leading the pest control sector in traffic growth. This rise, highlighted by RBC Capital Markets, suggests a tentative recovery in demand after a slow sprin...
Bitcoin price rose 1.2% to around $63,650 after buyers defended support near $62,700, showing short-term momentum improvement. However, nearly $390 million exited US spot Bitcoin ETFs last week, indicating cautious institutional demand. Key resistanc...
Kratos Defense & Security Solutions reported strong second-quarter results and raised its guidance for 2026, signaling confidence in continued growth. The company's backlog reached $2.08 billion, supported by new facilities aimed at turbojet engine p...
Delta Air Lines is re-establishing a strong presence in Texas by focusing on Austin after closing its Dallas/Fort Worth hub in 2005. The airline announced new flights from Austin to Paris and San Diego, citing Austin's booming economy and global conn...
